Results 61 to 70 of about 221,455 (333)

Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy

Frontiers in Immunology, 2022
Primary membranous nephropathy (pMN) is an auto-immune disease characterized by auto-antibodies targeting podocyte antigens resulting in activation of complement and damage to the glomerular basement membrane.
M. Teisseyre, M. Cremoni, Sonia Boyer-Suavet, Caroline Ruetsch, D. Graça, V. Esnault, V. Brglez, B. Seitz-Polski   +7 more
semanticscholar   +1 more source

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

, 2010
Rituximab, a monoclonal antibody which targets CD20 on B-cells, is now central to the treatment of a variety of malignant and autoimmune disorders. Despite this success a substantial proportion of B-cell lymphomas are unresponsive or develop resistance ...
French, R.R., Johnson, P.W.M., Cox, Kerry L., Chan, Claude H.T., Johnston, David A., Glennie, Martin J., Jarrett, T.C., Glennie, M.J., Verbeek, Sjef, Chan, H.T.C., Dixon, S.V., Mora Vidal, Regina, Wijayaweera, Sahan S., Cragg, Mark S., Lim, Sean H., Dixon, Sandra V., Verbeek, J.S., French, Ruth R., Wijayaweera, S.S., Jarrett, Timothy C., Cragg, M.S., Kim, Hyung J., Kerr, Jonathan P., Vidal, R.M., Johnston, D.A., Lim, S.H., Cox, K.L., Kerr, J.P., Johnson, Peter W.M., Beers, Stephen A., Kim, H., Beers, S.A.   +31 more
core   +1 more source

Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey

Pharmaceuticals, 2014
Biologics such as rituximab are an important component of oncology treatment strategies, although access to such therapies is challenging in countries with limited resources.
William H. Baer II, Archana Maini, Ira Jacobs   +2 more
doaj   +1 more source

HIV-associated multi-centric Castleman’s disease with multiple organ failure: cuccessful treatment with rituximab [PDF]

, 2010
Introduction: Multicentric Castleman's Disease (MCD), a lymphoproliferative disorder associated with Human Herpes Virus-8 (HHV-8) infection, is increasing in incidence amongst HIV patients.
Johns, RH, Lipman, M, Agarwal, B, Cwynarski, K, Doyle, T, Isaacson, PG, Cleverley, JR, Shaw, S   +7 more
core  

Biphasic Clinical Course of Pediatric Cytomegalovirus‐Associated Immune Thrombocytopenia: Early Poor Treatment Response but Favorable Long‐Term Outcomes

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Cytomegalovirus (CMV) is a recognized trigger of immune thrombocytopenia (ITP); however, its incidence and impact on disease course in children remain controversial. Therefore, we aimed to characterize the clinical course of pediatric patients with CMV‐associated ITP.
Oded Gilad, Ohad Atia, Osama Tanous, Dafna Brik Simon, Michal Dvori, Miriam Cohen, Tracie A. Goldberg, Efraim Bilavsky, Joanne Yacobovich, Orna Steinberg‐Shemer   +9 more
wiley   +1 more source

Hospitalised infections and rituximab administration among children and adolescents with systemic lupus erythematosus from 2009 to 2021

Lupus Science and Medicine
Background Rituximab is associated with high infection rates, but studies of infections following rituximab in youth with childhood-onset SLE (cSLE) are limited.
Esi M Morgan, Jonathan D Cogen, Jordan E Roberts, Anna V Faino, Mersine A Bryan   +4 more
doaj   +1 more source

Classical Complement Pathway Inhibition in a Pediatric Patient With Refractory Immune Thrombocytopenia

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Pediatric refractory immune thrombocytopenia (rITP) is generally characterized by persistent thrombocytopenia and failure to achieve a sustained response to multiple standard therapies. We report a 4‐year‐old female with congenital tufting enteropathy, post‐intestinal transplant patient on immunosuppressants, who developed severe rITP ...
Sarah Hsieh, Susmita Sarangi, Caileigh Pudela, Catherine M. Broome, Tara K. Suntum   +4 more
wiley   +1 more source

Hypokalemia after rituximab administration in nephrotic syndrome: two case reports

BMC Nephrology, 2023
Rituximab, a chimeric anti-CD20 monoclonal antibody, is an effective treatment for nephrotic syndrome. Hypokalemia is a rare adverse reaction among patients treated with rituximab although there have been extensive reports of acute and chronic adverse ...
Yiyun Song, Lin Ding, Xin An, Yi Zhao, Xianhua Li, Xiangdong Yang, Xiaoyan Xiao   +6 more
doaj   +1 more source

Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus

Annals of Internal Medicine, 2021
BACKGROUND B-cell depletion with rituximab is commonly used for patients with systemic lupus erythematosus (SLE) that is refractory to conventional therapy, but it yields variable responses.
M. Shipa, A. Embleton-Thirsk, M. Parvaz, L. Santos, P. Muller, K. Chowdhury, D. Isenberg, C. Doré, Caroline Gordon, M. Ehrenstein   +9 more
semanticscholar   +1 more source

Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus--report of 17 cases and review of the literature [PDF]

, 2013
Cutaneous manifestations occur frequently in systemic lupus erythematosus (SLE) and are pathognomonic in subacute-cutaneous lupus erythematosus (SCLE) and chronic cutaneous lupus erythematosus (CCLE).
Morris, SD, Hofmann, SC, Leandro, MJ, Isenberg, DA   +3 more
core